Borrelidin: A prospective drug

Indian Journal of Biotechnology

Volumn 9, Issue 1, 2010, Pages 18-23

  Bhikshapathi, D V R N ^a   Shravan Kumar, Y ^a   Madhusudan Rao, Y ^a   Kishan, V ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Borrelidin; CYP3A enzyme; Lipinski's rule; Platelets; Prothrombin time

Indexed keywords

ACETYLSALICYLIC ACID; BORRELIDIN; BUSPIRONE; CYTOCHROME P450 3A; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENZYME INHIBITION; INTERNATIONAL NORMALIZED RATIO; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; PROTHROMBIN TIME; RAT; THROMBOCYTE AGGREGATION INHIBITION;

RATTUS; RATTUS NORVEGICUS; STREPTOMYCES; STREPTOMYCES ROCHEI;

EID: 76549112043     PISSN: 09725849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Berger J, Jampolsky L M & Goldberg M W, Borrelidin a new antibiotic with anti-borrelia activity and penicillin enhancement properties, Arch Biochem, 22 (1949) 476-478.
2. Dorgerloh M, Kretschmer A, Schmidt R R, Steffens R, Zoebelein G et al, Borrelidin insecticide and herbicide, and its preparation by fermentation, Ger Offen, 11 (1988) DE 3607287.
3. Olano C, Moss S J, Brana A F, Sheridan M S, Math V et al, Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces parvulus Tu 4055: Insights into nitrile formation, Mol Microbiol, 52 (2004) 1745-1756.
4. Saisivam S, Bhikshapathi D V R N, Krishnaveni J & Kishan V, Isolation of borrelidin from Streptomyces californicus- An Indian soil isolate, Indian J Biotechnol, 7 (2008) 349-355.
5. Borrelidin- Producing polyketide synthetase and its use. WO/2004/058976 (World Intellectual Property Organization, Geneva) 2004.
6. Kazuro S & Satoshi O, Antiparasitic agents produced by microorganisms, Proc Jpn Acad, 81 (2004) 245-258.
7. Wakabayashi T, Kageyama R, Naruse N, Tsukahara N, Funahashi Y et al, Borrelidin is an angiogenesis inhibitor: Disruption of angiogenic capillary vessels in a rat aorta matrix culture model, J Antibiot, 50 (1997) 671-676.
8. Kawamura T, Liu D, Towle M J, Kageyama R & Tsukahara N, Anti-angiogenesis effects of borrelidin are mediated through distinct pathways: Threonyl-tRNA synthetase and caspases are independently involved in suppression of proliferation and induction of apoptosis in endothelial cells, J Antibiot, 56 (2003) 709-715.
9. Klans E, Fleck W, Pranser H, Tonew E & Zoepel P, A new method for the isolation of the antiviral antibiotic borrelidin, Zeitschrift fuer Allgemeine Mikrobiologie, 10 (1970) 367-369.
10. Wakabayashi T & Reina K, Angiogenesis inhibitor borrelidin derivatives manufacture with Streptomyces, Jpn Kokai Tokkyo Koho JP 09227549 (1997) 13.
11. st ACS National Meeting, Atlanta, USA, March 26-30, 2006.
12. Lipinski C A, Lombardo F, Beryl W D & Feeney P J, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv Drug Delivery Rev, 23 (1997) 3-25.
13. th, 2007.
14. Srinivas M, Srisilam K, Chandra Mohan E, Madhusudan Rao Y & Gerhard K E S, Development and validation of stereo selective HPLC method for the determination of the in vitro transport of nateglinide enantiomers in rat intestine, J Sep Sci, 30 (2007) 1875-1880.
15. PT-Determination, Erba Coag Uno Manual (Transonic Biomedicals Ltd, Germany) 1-13.
16. th 2007.
17. Lamberg T S, Kivisto K T & Neuvonen P J, Lack of effect of terfenadine on the pharmacokinetics of the CYP3A substrate buspirone, Pharmacol Toxicol, 84 (1999) 165-169.
18. nd edn, vol 179, (CRC Press, Boca Raton) 2008, 487-488.
19. Prothrombin time, Web MD, April'04 (2008) 1-3.
20. Hirsh J, Dalen J E, Poller L & Deykin D, Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range, Chest, 119 (2001) 8S-21S.